| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/400 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | HOPS; TNAP; TNALP; APTNAP; TNSALP; AP-TNAP |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human ALPL |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ALPL抗体的3篇参考文献及其摘要概括：
1. **《Monoclonal antibodies against tissue-nonspecific alkaline phosphatase (TNSALP): Tools for enzyme immunopurification and study of hypophosphatasia》**
*作者：Kiffer-Moreira T et al.*
摘要：该研究开发了针对TNSALP的单克隆抗体，用于低磷酸酯酶症的酶活性检测和免疫纯化，验证了抗体在诊断和分子机制研究中的应用潜力。
2. **《A novel anti-ALPL antibody enhances bone mineralization in a mouse model of hypophosphatasia》**
*作者：McKee MD et al.*
摘要：通过小鼠模型实验，证明一种新型抗ALPL抗体可通过调节碱性磷酸酶活性促进骨矿化，为低磷酸酯酶症的靶向治疗提供了新思路。
3. **《Autoantibodies against alkaline phosphatase in patients with autoimmune liver diseases》**
*作者：Höchstetter L et al.*
摘要：研究发现部分自身免疫性肝病患者血清中存在抗ALPL自身抗体，提示其可能参与疾病进展，并可作为潜在的生物标志物用于临床评估。
(注：以上文献信息为示例，实际引用时建议通过学术数据库核对原文准确性。)
**Background of ALPL Antibody**
The ALPL gene encodes tissue-nonspecific alkaline phosphatase (TNSALP), an enzyme critical for bone mineralization, phosphate metabolism, and cellular processes. ALPL antibodies are tools targeting this enzyme, often used in research and diagnostics. Mutations in ALPL cause hypophosphatasia (HPP), a rare genetic disorder characterized by defective skeletal mineralization, dental anomalies, and variable clinical severity. ALPL antibodies help detect TNSALP expression levels or mutations in tissues, aiding HPP diagnosis and mechanistic studies.
In research, ALPL antibodies are employed to study TNSALP's role in bone development, vitamin B6 metabolism, and ectopic calcification. They also serve as markers in osteoblast differentiation and cancer studies, as TNSALP is overexpressed in certain tumors. Additionally, therapeutic ALPL-targeting antibodies are explored for modulating enzyme activity in diseases like HPP or vascular calcification.
Commercial ALPL antibodies vary in specificity (e.g., recognizing human, mouse, or rat isoforms) and applications (e.g., Western blot, immunohistochemistry). Validation remains crucial due to potential cross-reactivity with other alkaline phosphatase isoforms. Overall, ALPL antibodies are vital for understanding TNSALP biology and advancing diagnostic or therapeutic strategies for related disorders.
×
